FDA’s lack of onsite inspections may have compromised drug quality, study says
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionBiologics/ biosimilars/ vaccinesBiotechnologyCompliancePharmaceuticalsUnited StatesRegulatory NewsJoanne S. EglovitchAudit/inspectionBiologics/ biosimilars/ vaccinesBiotechnologyCompliancePharmaceuticalsUnited States